<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251028067791N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-13</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of two type of anesthesia on pain intensity in PCNL surgery.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of erector spinae block and paravertebral block using ropivacaine on pain intensity and need for analgesics after percutaneous nephrolithotomy in patients of Firoozgar Hospital.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>92</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/87156</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: "My study is being conducted at a single center and aims to compare the effectiveness of two types of pain blocks in reducing the need for analgesics after nephrolithotomy. Therefore, the study design is single-center and aims to investigate the superiority of one method over the other.", Randomization description: Patients will be randomly assigned to one of the two groups (paravertebral block or quadratus lumborum block) using a random number table (or computer-generated randomization). The allocation will be performed by a person not involved in the intervention or outcome assessment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>postoperative pain after nephrolithotomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Ultrasound-guided Erector Spinae Plane Block (ESP block)with Ropivacaine 0.2%, volume 20-30 ml, administered preoperatively at the level of T8-T9 on the side of surgery. Intervention 2: Intervention group: Ultrasound-guided Paravertebral Block with Ropivacaine 0.2%, volume 20-30 ml, administered preoperatively at the level of T10-T11 on the side of surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Since this study is part of a resident thesis with limited scope and duration, there is currently no plan or requirement to share individual participant data. The dataset is small, and the primary goal is academic fulfillment, not broader data dissemination.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Robab maghsoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vanak Square, Shahid Valinejad Street, No. 11, Unit 6</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416733151</zip>
        <telephone>+98 914 411 0966</telephone>
        <email>rmaghsudy@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Robab maghsoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran, Vanak Square, Shahid Valinejad Street, No. 11, Unit 6</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1517963717</zip>
        <telephone>+98 914 411 0966</telephone>
        <email>rmaghsudy@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient's age is between 20 - 65.
BMI &lt;30 should be less than
Not be addicted to drugs
Do not take painkillers 48 hours before the procedure.
The duration of the procedure should be less than 3 hours.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient is older than 65 and younger than 20
The patient's BMI is greater than 30.
Have a drug addiction
If you have taken painkillers 48 hours before the procedure
If the procedure lasts more than 3 hours</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Calculus of kidney and ureter</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Ultrasound-guided Erector Spinae Plane Block (ESP block)with Ropivacaine 0.2%, volume 20-30 ml, administered preoperatively at the level of T8-T9 on the side of surgery.</i_keyword>
      <i_keyword>Intervention group: Ultrasound-guided Paravertebral Block with Ropivacaine 0.2%, volume 20-30 ml, administered preoperatively at the level of T10-T11 on the side of surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>*Pain intensity* measured by Visual Analog Scale (VAS) at defined postoperative intervals (e.g., 2, 6, 12, 24 hours)  - *Total analgesic consumption* (e.g., mg of morphine or equivalent) within the first 24 hours after surgery. Timepoint: At 1, 6, 12, and 24 hours postoperative and cumulative analgesic consumption within 24 hours after surgery. Method of measurement: 1: Visual Analog Scale (VAS), a 10-cm scale where 0 indicates no pain and 10 indicates worst imaginable pain.                                                          2:Total amount of analgesic drugs (e.g., morphine equivalents) recorded from patient charts during the first 24 hours postoperatively.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>1: Patient satisfaction level with pain control 2: Occurrence of complications related to the block (e.g. hypotension, nausea) 3: Time of first request for analgesics 4: Changes in vital signs after the block. Timepoint: at 1, 6, 12, and 24 hour postoperative. Method of measurement: 1.Patient satisfaction: Measured using a standardized 5-point Liker scale questionnaire postoperatively. 2.Complications (e.g., hypotension, nausea): Monitored and recorded by clinical observation and chart review.3.Time to first analgesic request: Recorded in hours from end of surgery until the first analgesic demand by patient, via nursing chart. 4.Vital signs: Measured using standard hospital monitoring equipment (blood pressure, heart rate, respiratory rate) and recorded at regular intervals postoperatively.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-10-25</approval_date>
        <contact_name>Ethics Committee in Research, Faculty of Medicine - Iran University of Medical Sciences</contact_name>
        <contact_address>Vali Asr Square, Shahamati Alley, No. 11, Unit 5 Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
